Prostate cancer has become a serious health problem that plagues older men, and many patients have metastasized by the time they are diagnosed. Therefore, it is important that prostate cancer patients are actively diagnosed and treated. Specialists have pointed out that high androgen levels in the body may be the culprit of prostate cancer, so endocrine therapy targeting androgens is one of the important tools in prostate cancer treatment. For example, androgen removal therapy (ADT) is a drug therapy or surgical procedure that is considered the standard of care for patients with newly diagnosed metastatic prostate cancer. There is a novel endocrine therapy drug for prostate cancer that inhibits androgen synthesis in testicular, adrenal and prostate tumors, a unique mechanism that has received widespread medical attention. In 2011, the drug was approved for clinical use in the United States, Canada and the European Union. In order to compare the effectiveness of this drug with prednisone and ADT combination therapy versus ADT alone in slowing the progression of metastatic prostate cancer, a multi-center clinical program for patients with primary metastatic prostate cancer in China is currently underway in several hospitals in China and has been approved by the State Food and Drug Administration. If you meet all the requirements of the program and sign the informed consent form to participate, you can receive the relevant free screening and medication, as well as regular observation and follow-up guidance as arranged by your healthcare provider. Main entry criteria: Male at least 18 years old; Histologically or cytologically confirmed adenocarcinoma; Positive scan results or metastases suggested in CT/MRI results; Swallowing medication whole; Note: The above are some of the main criteria, and the final entry criteria are in the hands of the program physicians.